Institute for Cell and Molecular Biosciences

Business & Development

Business and Development

We have an excellent track record for producing spin-out companies from our research.

We are part of a Bioscience Enterprise which underpins Newcastle’s Science City status, designated by the Government.

A number of our spin-out companies are evolving rapidly:

  • Prof Alastair Hawkins was one of the founders of Arrow Therapeutics Ltd, established in 1998, whose remit was to discover and develop antivirals. In 2007 Arrow Therapeutics Ltd. was purchased by AstraZeneca.
  • Prof Jeff Errington, FRS, FMedSci was the founder and Chief Scientific Officer of Prolysis Ltd, an antibacterial drug discovery company with two new classes of compounds in preclinical development, now part of Biota Pharmaceuticals Inc.
  • Prof Errington is also the founder and Scientific Director of Demuris Ltd, which exploits a unique collection of actinomycete bacteria to search for new natural product compounds with a wide range of therapeutic applications, especially antibiotics. The Demuris collection is also used to screen for natural products with other commercial uses, including high value chemicals, industrial enzymes and cosmeceuticals.
  • Prof Jeremy Lakey is scientific director and founder of Orla Protein Technologies a bio-nanotechnology company. In 2002, Orla was one of the winners in the BBSRC Biosciences Business Award and has received 2 DTI Innovation Awards.